Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Pompe Disease

Nov 01, 2024

5 Promising Pompe Disease Drugs in Early-stage Development

Oct 16, 2024

Transforming Pompe Disease Care: Latest Innovations and Strategic Advances in Treatment

Sep 30, 2024

The Transforming Pompe Disease Treatment Landscape in Emerging Markets

Sep 30, 2024

Pompe Disease Treatment Landscape

Sep 30, 2024

Pompe Disease: Causes, Symptoms, Diagnosis, Pathology, Current Marketed and Emerging Drugs in the Pipeline

Sep 30, 2024

Advances in Pompe Disease Treatment: From ERT to New Therapies

Sep 30, 2024

Navigating Challenges in Pompe Disease Treatment and Research in Eastern Europe

Jan 24, 2023

BeiGene’s Brukinsa Approval; FDA Approval to Seagen’s TUKYSA; NICE Recommends Alnylam’s Amvuttra; FDA Approves Brenzavvy for Type 2 Diabetes; Roche’s Tecentriq to be Filed for Early-stage Liver Cancer; FDA Lifts Hold on Astellas’ Pompe Gene Therapy

Dec 20, 2022

Fourth FDA Approval for AbbVie’s Vraylar; FDA Approves Ferring’s Adstiladrin for NMIBC; Merck and Moderna’s mRNA Cancer Vaccine Trial; EMA Recommends the CSL’s Gene Therapy for Hemophilia B; CHMP Backs Amicus’ Pompe Disease Therapy; Takeda Announces the Phase 3 AURORA Study Result

Apr 20, 2022

Top 12 Most Expensive Drugs in the US Healthcare Market

Newsletter/Whitepaper